1 completed, 1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Watch & Wait: new trials by email Literature Review of Watch & Wait trials Research Report on Watch & Wait
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-09-23 |
| Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma Surgical Resection, Maintenance Therapy Group - HCC - Hepatocellular Carcinoma, Watch & Wait | Recruiting | West China Hospital | 100 | 2026-03-01 | 2026-10-02 | |
| Non-OpeRative MANagement of Rectal Cancer Patients Capecitabine - Rectal Cancer, Chemoradiotherapy | Phase 2 | Completed | Kangbuk Samsung Hospital | 18 | 2018-02-01 | 2025-02-12 |
Carcinoma, Hepatocellular (1) · Lymphoma, Follicular (1) · Rectal Neoplasms (1)
Neoplasms (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
Capecitabine (1) · Observation (1)
Kangbuk Samsung Hospital (1) · M.D. Anderson Cancer Center (1) · West China Hospital (1)
China (1) · South Korea (1) · United States (1)
Dai Chihara, MD (1) · Dong-Hoe Koo (1)